Lifeboat Foundation

The ‘grandfather paradox’ of time travel has been puzzling philosophers, quantum physicists and novelists for years. Now there’s an answer as Cathal O’Connell reports.

Read more

China is already well on the way to establishing its own version of America’s GPS network with its Beidou satellite constellation, but now it is seeking to take navigation and timing to stellar levels.

In November China will launch the X-ray pulsar navigation satellite — XPNAV-1 — a satellite that will conduct the world’s first test of the possibilities of using the regular emission of X-ray signals from pulsars for spacecraft navigation.

The spacecraft will attempt to triangulate its position relative to the Sun using the highly regular emissions from pulsars.

Continue reading “China to launch pioneering pulsar navigation satellite in November” »

Want to reach for the stars? Here’s how to do it.

What happens when Charlie Rose attempts to interview a robot named “Sophia” for his 60 Minutes report on artificial intelligence.

What if robots could figure out more things on their own and share that knowledge among themselves?

Availability: 3–5 years.

Read more

More than 20,000 women are diagnosed with ovarian cancer each year in the United States, most of whom have advanced disease. Although chemotherapy can put the disease into remission, it often recurs and the treatment’s effectiveness tends to wane over time. As a result, ovarian cancer is the fifth most-common cause of cancer death in women.

On Saturday, a team of researchers including Stanford oncologist Jonathan Berek, MD, presented the results of an international, multi-center phase-3 clinical trial of a new oral medication called niraparib in 553 women with advanced, recurrent ovarian cancer at the annual meeting of the European Society for Molecular Oncology in Copenhagen. Berek, the Laurie Kraus Lacob Professor and director of the Stanford Women’s Cancer Center, supervised Stanford’s involvement in the trial.

The aim of the study was to see whether niraparib could prolong the length of remission, also known as “progression-free survival,” in the women when compared to treatment with a placebo. As Berek described the niraparib treatment for me in an phone call, “This is a daily oral treatment with relatively low toxicity. Importantly, women don’t have to go to the hospital for regular infusions and are unlikely to experience significant hair loss.”

Continue reading “In International Phase-3 Clinical Trial, New Drug Shown To Prolong Ovarian Cancer Remission” »

Cybathlon 2016

The very first Cybathlon in the world took place today. The event was completely sold out: some 4,600 visitors packed into the SWISS Arena Kloten to support the 66 teams from various countries. The pilots pitted their skills in six disciplines and demonstrated most impressively how novel technologies can assist people with disabilities in their daily life.